Literature DB >> 6156134

Mastocytosis.

J Fine.   

Abstract

Mastocytosis implies involvement by excessive numbers of mast cells, of skin and/or other organs. Symptoms may be absent to severe, even occasionally life-threatening. H1- and H2-blocking agents potentially may relieve symptoms, but do nothing to prevent systemization. At present no specific combination chemotherapy regimen has been shown to be markedly effective in a large controlled study. Mithramycin may be of benefit in relieving localized bone pain, although confirmation of this observation in large numbers of patients is needed. PUVA may be a viable approach to symptomatic treatment of otherwise poorly controlled urticaria pigmentosa. In children, urticaria pigmentosa is a relatively benign disease without an increased risk of later systemic involvement. In adults, however, other organs by be involved, with resultant increased morbidity and mortality. Without specific symptoms to a particular organ system, elaborate and expensive staging work-up is not indicated, at least until there is evidence that a reproducibly effective therapy for systemic disease exists.

Entities:  

Mesh:

Year:  1980        PMID: 6156134     DOI: 10.1111/j.1365-4362.1980.tb00272.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  4 in total

1.  Paediatric mastocytosis.

Authors:  M C Carter; D D Metcalfe
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

Review 2.  Mastocytosis and disorders of mast cell proliferation.

Authors:  Joanne K Simpson; Dean D Metcalfe
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

Review 3.  Urticaria and angioedema.

Authors:  B A Burrall; A C Huntley
Journal:  Clin Rev Allergy       Date:  1985-02

4.  Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material.

Authors:  Christian Kähler; Sabine Didlaukat; Alfred C Feller; Hartmut Merz
Journal:  Diagn Pathol       Date:  2007-09-27       Impact factor: 2.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.